[go: up one dir, main page]

IL127306A0 - Combination therapy - Google Patents

Combination therapy

Info

Publication number
IL127306A0
IL127306A0 IL12730698A IL12730698A IL127306A0 IL 127306 A0 IL127306 A0 IL 127306A0 IL 12730698 A IL12730698 A IL 12730698A IL 12730698 A IL12730698 A IL 12730698A IL 127306 A0 IL127306 A0 IL 127306A0
Authority
IL
Israel
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
IL12730698A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL127306A0 publication Critical patent/IL127306A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12730698A 1997-12-03 1998-11-26 Combination therapy IL127306A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6726897P 1997-12-03 1997-12-03

Publications (1)

Publication Number Publication Date
IL127306A0 true IL127306A0 (en) 1999-09-22

Family

ID=22074866

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12730698A IL127306A0 (en) 1997-12-03 1998-11-26 Combination therapy

Country Status (7)

Country Link
EP (1) EP0920864A1 (fr)
JP (1) JPH11228447A (fr)
KR (1) KR19990062718A (fr)
AU (1) AU9605598A (fr)
CA (1) CA2255318A1 (fr)
HU (1) HUP9802795A3 (fr)
IL (1) IL127306A0 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0858340A4 (fr) * 1995-11-01 1999-12-29 Merck & Co Inc Traitement combine du diabete et de l'obesite
US6246876B1 (en) 1997-11-13 2001-06-12 Telefonaktiebolaget L M Ericsson (Publ) Synchronization messages for hand-off operations
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
AU2571300A (en) * 1999-02-16 2000-09-04 Kaneka Corporation Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
WO2001021577A2 (fr) * 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
FR2814678B1 (fr) † 2000-10-04 2002-12-20 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
JP4733922B2 (ja) * 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2007075555A2 (fr) * 2005-12-21 2007-07-05 Schering Corporation Combinaison d'un antagoniste/agoniste inverse de h3 et d'un moderateur de l'appetit
WO2007139062A1 (fr) * 2006-05-30 2007-12-06 Kyorin Pharmaceutical Co., Ltd. Agent thérapeutique contre l'obésité et méthode de traitement prophylactique et thérapeutique de l'obésité
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
JP6253451B2 (ja) 2014-02-05 2017-12-27 学校法人自治医科大学 満腹感持続剤および満足感を維持する方法
DK3393655T3 (da) 2015-12-22 2021-03-15 Zogenix International Ltd Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP4201427A1 (fr) 2016-08-24 2023-06-28 Zogenix International Limited Formulation pour inhiber la formation d'agonistes de 5-ht 2b et procédés d'utilisation de celle-ci
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019216919A1 (fr) 2018-05-11 2019-11-14 Zogenix International Limited Compositions et méthodes pour traiter la mort subite provoquée par la crise épileptique
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977124A (en) * 1995-05-10 1999-11-02 Pfizer Inc. β-adrenergic agonists
JPH11504648A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作動性アゴニスト
EP0858340A4 (fr) * 1995-11-01 1999-12-29 Merck & Co Inc Traitement combine du diabete et de l'obesite

Also Published As

Publication number Publication date
JPH11228447A (ja) 1999-08-24
HU9802795D0 (en) 1999-01-28
AU9605598A (en) 1999-06-24
HUP9802795A3 (en) 2000-01-28
HUP9802795A2 (hu) 1999-08-30
CA2255318A1 (fr) 1999-06-03
EP0920864A1 (fr) 1999-06-09
KR19990062718A (ko) 1999-07-26

Similar Documents

Publication Publication Date Title
EG24678A (en) Combination therapy
GB9708484D0 (en) Therapeutic agents
ZA987843B (en) Combination therapy.
GB9708945D0 (en) Therapeutic agents
IL127306A0 (en) Combination therapy
GB9704948D0 (en) Therapeutic agents
ZA982368B (en) New therapeutic combinations
GB9702524D0 (en) Therapeutic agents
GB9711753D0 (en) Therapeutic agents
GB9713707D0 (en) Therapeutic agents
GB9711114D0 (en) Therapeutic agents
GB9700939D0 (en) Therapy
GB9816556D0 (en) Therapy
GB9702392D0 (en) Therapeutic agents
GB9700555D0 (en) Therapeutic agents
GB9723999D0 (en) Therapeutic use
GB9726701D0 (en) Therapeutic use
GB9726702D0 (en) Therapeutic use
GB9806039D0 (en) Therapy
GB9704885D0 (en) Therapy
GB9605466D0 (en) Therapy
GB9605525D0 (en) Therapy
GB9721177D0 (en) Therapeutic use
GB9717425D0 (en) Therapeutic use
GB9721221D0 (en) Therapeutic use